Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.73 |
| ▸ | MEN1 | O00255 | 8/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.73 |
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853072 | 1.00 | LMNA (0.73) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL17653922 | 0.87 | LMNA (0.56) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL17653920 | 0.87 | LMNA (0.56) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL20560143 | 0.85 | LMNA (0.67) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5523784 | 0.85 | MEN1 (0.67) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL584346 | 0.85 | ALDH1A1 (0.73) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL6813819 | 0.84 | LMNA (1.00) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL6717028 | 0.83 | LMNA (0.64) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1454593 | 0.83 | MEN1 (0.72) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5881545 | 0.83 | LMNA (0.63) | LMNAMEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317430-B1 | (2-AZABICYCLO [2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20040039045-A1 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | claimed |
| EP-4376955-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-06-05 | — | — | EP | disclosed |
| US-20240156788-A1 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | NORTH CAROLINA STATE UNIVERSITY | 2024-05-16 | — | — | US | disclosed |
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2024-02-15 | — | — | US | disclosed |
| US-11883384-B2 | Substituted 2-aminobenzimidazoles analogs as antibiofilm agents | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4237418-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Blueprint Medicines Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023164358-A1 | GLP-1R MODULATING COMPOUNDS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-08-31 | — | — | WO | disclosed |
| WO-2006033632-A1 | Benzimidazole derivatives and their use as cannabinoid receptor ligands I | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1636214-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | Astrazeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| US-7008955-B2 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | MERCK PATENT GMBH (DE) | 2006-03-07 | — | — | US | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030762-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030732-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030733-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004108712-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| US-20040039045-A1 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | TYMP, DPYD, TYMS | LMNA 2293/4885MEN1 3891/4885KMT2A 3586/4885 |
| US-20040039045-A1 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | CHRNA1, CHRNA10, CHRNB1 | LMNA 4319/4885MEN1 2964/4885KMT2A 1979/4885 |
| US-11883384-B2 | Substituted 2-aminobenzimidazoles analogs as antibiofilm agents | ITGB3, ITGB2, ITGAM | LMNA 4746/4885MEN1 4722/4885KMT2A 2421/4885 |
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LMNA 3295/4885MEN1 370/4885KMT2A 4175/4885 |
| US-20240156788-A1 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | ITGB3, ITGB2, ITGAM | LMNA 4746/4885MEN1 4722/4885KMT2A 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.